跳至主要内容
临床试验/EUCTR2015-002963-40-ES
EUCTR2015-002963-40-ES进行中(未招募)不适用

Impact of treatment with Dapagliflozin (SGLT2 inhibitor) in metabolic control and glycemic pattern in type 1 diabetic patients - IDAPADM1

Dra Cristina Avendaño Sola0 个研究点开始时间: 2015年7月31日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • (1)Women or men aged 18-55 years od oldf at the time of completion of the informed consent.
  • (2)Written informed consent in conformity with local legislation obtaines before the performance of any procedure.
  • (3)Patients with a diagnosis of type 1 diabetes mellitus (Diabetes diagnosed before 30 years old in a patient without overweight/obesity or diabetes diagnosed before 45 years old with evidence of positive pancreatic autoantibodies)
  • (4)Treatment with multiple daily dose of insulin (1-2 injections of Glargina/Detemir with 3 injections of rapid insulin analogues) or continous subcutaneous insulin infusion therapy
  • (5)HbA1c greater than 7% in at least two consecutive blood tests (separated at least for 3 months) performed during the past 6 months previous to the beginning of the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 57
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • (1)Inability to give inform consent in the absence of a legal guardian
  • (2)Pregnancy or lactation
  • (3)If there are any clijnical, biochemical, cognitive, social or psycosocial factors (considered by the investigador) that could negative influence the study or patient.
  • (4)Liver disease (history of chronic liver disease or alteration in liver function tests: AST, ALT, bilirrubin, GGT)
  • (5)Renal failure (MDRD < 60 ml/min)
  • (6)History of multiple urinary tract or mycotic genital infections
  • (7)History of baldder cancer
  • (8)History of electrolyte disorders (SIADH, insipid diabetes, hyponatremia)
  • (9)Treatment with loop diuretics
  • (10)Haven received any drug under investigation, including antivirals, during the previous 6 months of starting the study.

研究者

发起方
Dra Cristina Avendaño Sola

相似试验